NASDAQ · ACHL
Healthcare · Biotechnology
$1.48
Up+$0.01 (+0.68%)
Updated Aug 14, 2026, 4:50 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ACHL does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ACHL.
ACHL research
Company profile and research snapshot.
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 5, 2024 | Piper Sandler | Neutral | — |
| Apr 5, 2024 | Chardan Capital | Buy | — |
| Dec 14, 2023 | B of A Securities | Underperform | — |
| Aug 7, 2023 | Chardan Capital | Buy | — |
| May 11, 2023 | Chardan Capital | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Feb 28, 2025
Achilles Therapeutics announced its intention to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and deregister from the SEC, in connection with the company's planned members' voluntary liquidation.
Benzinga · Dec 24, 2024
Achilles Therapeutics announced the sale of its TRACERx and Material Acquisition Platform (MAP) assets to AstraZeneca for $12 million, concluding its strategic review.
GlobeNewswire Inc. · Nov 19, 2024
Achilles Therapeutics announced that its American Depositary Shares (ADSs) will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective November 19, 2024. The transfer is due to the company's failure to meet the minimum bid price requirement on the Nasdaq Global Market, and it will provide an additional 180 days to regain compliance.
GlobeNewswire Inc. · Nov 14, 2024
Achilles Therapeutics announced its Q3 2024 financial results, including a cash position of $86.1 million and the discontinuation of its TIL-based cNeT program. The company has engaged BofA Securities to explore strategic options.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ACHL.
No results
No recent SID articles mention ACHL.
